Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq: CNTA) in a blockbuster transaction valued at up to $7.8 billion. This acquisition marks a watershed moment for the treatment of sleep-wake disorders and underscores the intense competition in the "orexin gold rush." At the heart of this deal is cleminorexton (ORX750), a developmental drug that clinical data suggests could become the definitive standard of care for narcolepsy and idiopathic hypersomnia.
This feature explores the evolution of Centessa from a sprawling "hub-and-spoke" experiment into a hyper-focused neuroscience powerhouse, the clinical breakthroughs of its lead asset, and the strategic implications of Eli Lilly’s latest move in its quest for dominant market share in high-growth therapeutic areas.
Historical Background
Centessa Pharmaceuticals was founded in late 2020 by Medicxi, a prominent life sciences venture capital firm, as a radical experiment in drug development. Launched officially in February 2021, the company was initially structured as a "hub-and-spoke" network of ten private biotech firms. Each subsidiary—including Orexia Therapeutics, Palladio Biosciences, and ApcinteX—operated with its own scientific team and focused on a single asset or pathway, while a central management team provided capital and shared expertise.
Following a high-profile IPO in May 2021 at $20.00 per share, Centessa initially struggled to find its footing. In 2022, the company faced significant setbacks, including the discontinuation of its lead Phase 3 program, lixivaptan, for rare kidney disease due to liver safety concerns. This prompted a dramatic pivot in 2023. Under founding CEO Saurabh Saha, Centessa transitioned from a diversified conglomerate into a "pure-play" orexin company, shedding multiple non-core assets to prioritize its most promising neuroscience candidate: ORX750, now known as cleminorexton.
Business Model
At its inception, Centessa’s business model was a departure from the traditional biotech corporate structure. By operating as a "hub," the parent company aimed to mitigate the risks associated with a single-drug pipeline by diversifying across multiple therapeutic areas like oncology, hematology, and rare diseases. This asset-centric model allowed individual "spoke" companies to maintain the agility of a startup without the administrative burden of a public entity.
However, the 2023 strategic pivot largely abandoned the "spoke" model in favor of a centralized development team focused on the orexin receptor 2 (OX2R) agonist program. By March 2026, Centessa’s revenue model remained pre-commercial, relying entirely on capital markets and strategic partnerships. Its value proposition was built on its proprietary chemistry and the rapid clinical progression of its orexin portfolio, which includes the lead drug cleminorexton and follow-on assets ORX142 and ORX489.
Stock Performance Overview
Centessa's stock (Nasdaq: CNTA) has experienced a volatile yet ultimately rewarding journey for long-term investors. After its 2021 IPO at $20.00, the stock hit a series of lows in late 2022 and early 2023, bottoming out near $2.50 as the market reacted negatively to the discontinuation of lixivaptan and ZF874.
The recovery began in late 2024 as early data for cleminorexton began to surface. By early 2025, CNTA was trading in the $10-$12 range. As Phase 2a results surpassed expectations in late 2025, the stock surged into the $20s. On March 31, 2026, following the announcement of the Eli Lilly acquisition at $38.00 per share upfront plus a $9.00 CVR, CNTA shares jumped over 45% to stabilize near the deal price, representing a nearly 1,500% gain from its 2023 lows.
Financial Performance
As of its last quarterly filing in late 2025, Centessa maintained a robust financial position for a mid-stage biotech firm. The company reported cash and cash equivalents of $404.1 million, providing a runway into mid-2027. This financial health was a key differentiator, as it allowed management to advance three different orexin assets simultaneously without immediate fear of dilution.
While the company has yet to generate revenue from product sales, its valuation has been driven by the multi-billion-dollar potential of the narcolepsy market. The acquisition deal by Eli Lilly values Centessa’s equity at approximately $6.3 billion upfront, with the potential to reach $7.8 billion if regulatory milestones are met. For Lilly, the transaction is expected to be slightly dilutive to earnings in the short term but highly accretive by 2028-2029.
Leadership and Management
The leadership of Centessa has been instrumental in its survival and eventual multi-billion-dollar exit. Dr. Saurabh Saha, an alum of Bristol Myers Squibb and Atlas Venture, served as the founding CEO and navigated the company through its 2022 identity crisis.
In early 2026, the company underwent a strategic leadership transition, appointing Dr. Mario Alberto Accardi as CEO. Dr. Accardi was the original founder of Orexia Therapeutics and is widely credited as the architect of the cleminorexton program. His appointment signaled to the market—and to potential acquirers like Eli Lilly—that the company was fully committed to its neuroscience mission. Dr. Saha transitioned to an advisory role to the board, ensuring continuity during the acquisition negotiations.
Products, Services, and Innovations
The crown jewel of Centessa’s portfolio is cleminorexton (ORX750), an oral, highly potent, and selective OX2R agonist. Narcolepsy is primarily caused by the loss of orexin-producing neurons in the brain, which leads to excessive daytime sleepiness (EDS) and cataplexy. Cleminorexton works by mimicking the action of orexin at the receptor level, effectively "flipping the switch" to maintain wakefulness.
The innovation behind cleminorexton lies in its selectivity and potency. In the Phase 2a CRYSTAL-1 study, the drug demonstrated a >20-minute improvement in the Maintenance of Wakefulness Test (MWT) for patients with Narcolepsy Type 1 (NT1) and a near-normalization of sleepiness scores for those with Narcolepsy Type 2 (NT2). Unlike earlier generations of wake-promoting agents, cleminorexton targets the underlying cause of the disease without the significant side effects associated with stimulants.
Competitive Landscape
Centessa operates in one of the most competitive niches in biotechnology. Its primary rivals include:
- Takeda Pharmaceutical Company (NYSE: TAK): Takeda is currently in Phase 3 with oveporexton (TAK-861) and is considered the frontrunner in terms of time-to-market for NT1.
- Alkermes plc (Nasdaq: ALKS): Alkermes is developing alixorexton (ALKS 2680), which has shown strong Phase 2 data and is also moving into Phase 3.
- Jazz Pharmaceuticals (Nasdaq: JAZZ): The current market leader in narcolepsy with its oxybate franchise (Xyrem/Xywav), Jazz is under pressure to innovate as orexin agonists threaten to disrupt the traditional treatment paradigm.
Eli Lilly’s acquisition of Centessa is seen as a direct challenge to Takeda’s lead, as cleminorexton has shown superior data in the NT2 and Idiopathic Hypersomnia (IH) populations, potentially giving it a broader label.
Industry and Market Trends
The "Orexin Gold Rush" is the defining trend in sleep medicine for 2026. For decades, the treatment for narcolepsy relied on sedative-hypnotics and stimulants that managed symptoms but did not address the orexin deficiency. The shift toward orexin agonists represents a move toward disease-modifying therapy.
Furthermore, the broader pharmaceutical industry is seeing a resurgence in neuroscience M&A. With many blockbuster drugs in oncology and immunology facing patent cliffs, companies like Eli Lilly, Bristol Myers Squibb, and AbbVie are aggressively pursuing high-growth areas like neuropsychiatry and sleep disorders to replenish their pipelines.
Risks and Challenges
Despite the enthusiasm surrounding the Eli Lilly acquisition, significant risks remain.
- Regulatory Hurdles: Cleminorexton has yet to enter Phase 3 registrational trials. Any unforeseen safety issues or failure to replicate Phase 2 efficacy in a larger population could derail the program.
- Safety Profile: Previous orexin agonists from other companies were halted due to liver toxicity. While cleminorexton has shown a clean safety profile to date, long-term safety data is still pending.
- Integration Risk: Merging a specialized biotech like Centessa into a behemoth like Eli Lilly can sometimes lead to talent attrition or delays in clinical development.
Opportunities and Catalysts
The primary opportunity lies in the $9.00 Contingent Value Right (CVR) associated with the deal. For investors who continue to hold or trade the CVR, the upcoming catalysts include:
- Q1 2027: Expected initiation of the Phase 3 global registrational program for cleminorexton in NT1.
- 2028: Potential FDA submission and approval for NT2 and IH indications.
- Expansion: The use of OX2R agonists in other conditions characterized by excessive sleepiness, such as Parkinson’s disease-related EDS or sleep apnea.
Investor Sentiment and Analyst Coverage
Prior to the buyout, Wall Street sentiment on CNTA had turned overwhelmingly positive. Analysts at major firms like Jefferies and Goldman Sachs had highlighted the "best-in-class" potential of ORX750 throughout 2025. Following the acquisition announcement, most analysts have moved their ratings to "Tender" or "Market Perform," aligning their price targets with the $38.00 cash offer. Institutional ownership remains high, with major positions held by Medicxi, T. Rowe Price, and Vanguard, all of whom are expected to benefit significantly from the premium paid by Lilly.
Regulatory, Policy, and Geopolitical Factors
The FDA has shown a willingness to expedite the review of orexin agonists due to the high unmet need in the narcolepsy community. Cleminorexton has already received Breakthrough Therapy Designation, which facilitates more frequent communication with the FDA.
From a policy perspective, the Inflation Reduction Act (IRA) continues to influence M&A strategies. Large pharma companies are increasingly looking for "small molecule" drugs that have a clear path to high-volume commercial success before price negotiation windows open. Cleminorexton fits this profile perfectly, offering a high-value treatment for a chronic condition.
Conclusion
The acquisition of Centessa Pharmaceuticals by Eli Lilly marks the end of a remarkable corporate journey. From its experimental "hub-and-spoke" origins to its near-collapse in 2022, and finally to its emergence as the premier player in the orexin space, Centessa serves as a case study in the power of strategic focus in biotechnology.
For Eli Lilly, this $7.8 billion bet on cleminorexton is a clear signal of its intent to dominate the next generation of neuroscience. For the medical community and patients, it represents the most promising hope yet for a treatment that truly addresses the biological root of narcolepsy. As the deal heads toward closing in the third quarter of 2026, the focus will now shift to the Phase 3 data that will determine if cleminorexton can live up to its "best-in-class" billing.
This content is intended for informational purposes only and is not financial advice. As of the publication date (3/31/2026), the author holds no positions in any of the companies mentioned.
